Capula Management LTD Vertex Pharmaceuticals Inc Transaction History

Capula Management LTD

  • $9.23 Billion
  • Q3 2024

A detailed history of Capula Management LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Capula Management LTD holds 174 shares of VRTX stock, worth $71,023. This represents 0.0% of its overall portfolio holdings.

Number of Shares
174
Holding current value
$71,023
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$460.0 - $505.78 $80,040 - $88,005
174 New
174 $80,000
Q1 2024

May 09, 2024
BUY
$407.69 - $446.08 $401,982 - $439,834
986 New
986 $412,000
Q4 2021

Feb 14, 2022
SELL
$177.01 - $223.45 $1.59 Million - $2.01 Million
-8,995 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$181.39 - $202.99 $1.63 Million - $1.83 Million
8,995 New
8,995 $1.63 Million
Q2 2021

Aug 13, 2021
SELL
$187.49 - $221.1 $1.04 Million - $1.23 Million
-5,547 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$207.02 - $241.31 $491,258 - $572,628
2,373 Added 74.76%
5,547 $1.19 Million
Q4 2020

Feb 16, 2021
BUY
$207.01 - $276.09 $348,604 - $464,935
1,684 Added 113.02%
3,174 $750,000
Q3 2020

Nov 16, 2020
BUY
$255.65 - $303.1 $283,004 - $335,531
1,107 Added 289.03%
1,490 $405,000
Q2 2020

Aug 14, 2020
BUY
$225.48 - $295.8 $86,358 - $113,291
383 New
383 $111,000
Q1 2020

May 15, 2020
SELL
$199.77 - $247.81 $2,796 - $3,469
-14 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$166.71 - $223.91 $3,334 - $4,478
-20 Reduced 58.82%
14 $3,000
Q3 2019

Nov 14, 2019
BUY
$166.23 - $187.09 $5,651 - $6,361
34 New
34 $6,000

Others Institutions Holding VRTX

# of Institutions
1,724
Shares Held
221M
Call Options Held
1.58M
Put Options Held
1.36M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Capula Management LTD Portfolio

Follow Capula Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capula Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Capula Management LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email